Australia’s Therapeutic Goods Administration has approved Celltrion’s Herzuma—the country’s first biosimilar trastuzumab—referencing Herceptin.
Australia’s Therapeutic Goods Administration (TAG) has approved Celltrion’s Herzuma—the country’s first biosimilar trastuzumab—referencing Herceptin.
While Celltrion is in discussions with affiliates concerning distribution channels for the drug approved to treat HER2-positive cancers, it has not yet decided on a launch date. "We will do our best to quickly enter the market so that cancer patients in Australia can benefit from high-quality biopharmaceuticals at a reasonable price," the Korean drug maker indicated in a corporate statement.
The trastuzumab biosimilar will join 2 other anticancer biosimilars on the list of TAG’s approved biosimilars—2 rituximab products referencing Rituxan have been approved. Other biozimilars authorized in Australia include adalimumab, etanercept, infliximab, filgrastim, epoetin alfa, insulin glargine, and follitropin alfa. (Unlike the United States, Australia addresses follow-on insulins and human follicle-stimulating hormones as biosimilars.)
Many of these products are reimbursable on the national Pharmaceutical Benefits Scheme, and 3 have been designated as substitutable for their reference products at the pharmacy level: Brenzys (an etanercept biosimilar referencing Enbrel), Renflexis, and Inflectra (both infliximab biosimilars referencing Remicade).
Australia has been making a marked effort to increase its uptake of biosimilars, and recently announced that it would implement 2 “uptake drivers” as a matter of national policy: encouraging prescribing of biosimilars over branded drugs for new patients, and providing a faster and simpler preapproval process for patients to receive a biosimilar drug than a branded drug. The drivers, say the Australian government, are expected to be time-limited initiatives that will support the acceptance of these products and positively impact market behavior.
The first product to become subject to the uptake drivers was Brenzys in December 2017, followed by both infliximab biosimilars in July 2018. The government published fact sheets on the biosimilars, with separate documents made available to prescribers, pharmacists, and patients or their caregivers.
The decision to institute the drivers follows 2016 research from Australia’s Department of Health that found that specialist physicians and pharmacists were significantly more likely to prescribe and dispense branded biologics than biosimilars, a finding that was seen to be a function of specialists’ concerns about biosimilarity and about switching stable patients from reference to biosimilar products.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.